

CORPORATE PROFILE

ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX)

ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical research and development company committed to the commercialization of new therapies to treat cancer and viral disease. The company seeks to improve upon existing therapies or to develop novel treatments that address significant problems such as drug metabolism, toxicity, bioavailability and resistance.



LEAD PRODUCT

CoFactor™ (ANX-510) is a chemotherapy biomodulator of 5-fluorouracil (5-FU), a widely used cancer drug. CoFactor has demonstrated the ability to increase survival and reduce toxicity in metastatic colorectal cancer patients when compared historically with other approved therapies. Preliminary results for the Phase II CoFactor clinical trial showed a 65% overall clinical benefit and a 38% objective response rate, and no grade 3 or 4 gastrointestinal or hematological toxicities in measurable patients. ADVENTRX has initiated patient treatment in its EU-based international Phase IIb trial with CoFactor in metastatic colorectal cancer. Furthermore, the Company plans to begin dosing patients in a Phase III CoFactor clinical trial in metastatic colorectal cancer in the US in Q1 2006.

OTHER COMPOUNDS

Selone™ is an organoselenone-based compound, which has shown effectiveness, at even relatively low concentrations, in human ovarian, breast, lung and head/neck cancers, and in leukemias and lymphomas, based upon current *in vitro* screening methods. Preclinical studies with Selone have demonstrated effectiveness in treatment of leukemia as well as in a variety of human tumor cell lines in laboratory testing.

The Company's anti-HIV compounds include Thiovir™ and BlockAide/CR™ and are currently in preclinical development. ADVENTRX holds exclusive licenses to use patents and other intellectual property for these compounds.

Product	Development Stage & Milestones
CoFactor™ (ANX-510)	<p>1997 - Published results of a Phase I/II trial in Europe for metastatic GI and breast cancers</p> <p>CoFactor Phase II US trial in metastatic colorectal cancer</p> <p>1Q 2004 - Initiated trial with CoFactor/5-FU as first-line therapy</p> <p>1Q 2005 - Met primary endpoint for response and completed patient enrollment</p> <p>2Q 2005 - Announced preliminary clinical results</p> <p>Other CoFactor clinical trials in metastatic colorectal cancer</p> <p>2Q 2005 - Clearance received under a special protocol assessment (SPA) to initiate US Phase III pivotal trial</p> <p>2Q 2005 - Clearance received in UK to initiate international Phase IIb clinical trial; patient treatment initiated</p> <p>2005 - Pursue global partnership opportunities</p>
Selone™	Further preclinical testing planned during 2005
Thiovir™	Further preclinical testing planned during 2005

CONTACT INFORMATION

ADVENTRX Pharmaceuticals, Inc.
6725 Mesa Ridge Rd., Suite 100
San Diego, CA 92121
Ioana C. Hone
Assoc. Director, Investor Relations
Tel: 858.552-0866
Fax: 858.552.0876
ir@adventrx.com
www.adventrx.com

MARKET SUMMARY

As of September 28, 2005

Exchange: AMEX
Ticker: ANX
Recent stock price : \$3.23
Market cap: \$213M
52-week high/low: \$4.16-\$0.78
Shares outstanding: 65.9M
Float (non-affiliate): 46.28M
Fiscal year end: December 31

INVESTMENT CONSIDERATIONS

- Positive preliminary CoFactor Phase II tumor response and toxicity data presented in Q2 2005.
- Patient treatment initiated in Phase IIb international trial with CoFactor in metastatic colorectal cancer (mCRC).
- Clearance granted under an SPA to conduct a Phase III pivotal trial using CoFactor in mCRC.
- Therapies address global multi-million dollar growth markets with significant unmet medical needs.
- Strong IP portfolio with composition of matter and method of use patents and patent applications in the US and worldwide; exclusive rights from leading universities.
- Net cash position of \$8.1 million (at June 30, 2005) and no debt. Completion in July 2005 of a \$20 million private placement of common stock and warrants. Funds from this transaction to be reflected on balance sheet in the third quarter ending September 30, 2005.

BUSINESS STRATEGY

ADVENTRX will actively seek partners upon completion of its Phase II trial and advancement to Phase III CoFactor trials. This strategy enables the Company to maintain its role as a clinical development organization, while developing the option to distribute its products through strategic partnerships and/or licensing opportunities, or to create a sales and marketing infrastructure, as warranted.

ADVENTRX plans to commit the majority of its resources to the development of CoFactor, where the Company sees the most significant near-term opportunity for market approval. The Company has secured additional capital and strengthened its senior management to support the Company's drug development pipeline.

The Company is directed by a highly experienced biopharmaceutical management team. Disciplines include clinical medicine, product development, technology acquisition and development, intellectual property, venture capital financing, government grants, corporate licensing, and joint ventures.

PARTNERSHIPS

ADVENTRX partners include research, clinical research and manufacturing organizations. ADVENTRX funding has supported administrative and laboratory operations at the University of Southern California and Sahlgrenska University Hospital in Göteborg, Sweden, to enable further development and testing of drug candidates in both research and clinical settings. In addition, the Company maintains manufacturing and clinical research organization (CRO) partnerships with:

- Merck Eprova AG – manufacturing of CoFactor for clinical trials
- Synteract, Inc. – CRO partner for ADVENTRX in CoFactor studies in the US
- Pharm-Olam International – CRO partner for ADVENTRX in CoFactor clinical studies outside the US

POSITIVE RESPONSE DATA FOR TOTAL PATIENT ENROLLMENT IN PHASE II TRIAL REPORTED with COFACTOR in METASTATIC COLORECTAL CANCER

In June 2005, ADVENTRX announced that response data for all patients enrolled in the Phase II CoFactor clinical trial showed a 65% overall clinical benefit and a 38% objective response rate in measurable patients treated with CoFactor and 5-FU as a first-line treatment of metastatic colorectal cancer. Furthermore, patients enrolled in the trial have exhibited no grade 3 or 4 gastrointestinal or hematological toxicity. Preliminary results of the Phase II trial were published in the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings and at the 7th World Congress on GI Cancer.

The trial is an open-label, single-arm, Simon two-stage study design to evaluate safety and efficacy of weekly treatment with CoFactor and 5-FU in patients with metastatic colorectal cancer.

This Corporate Profile contains forward-looking statements about ADVENTRX Pharmaceuticals, Inc. (the "Company") including, without limitation, the benefits and performance expected from the use of our potential products, the timing and success of clinical trials and the receipt of required approvals from the United States Food and Drug Administration and other regulatory agencies. Forward-looking statements are based on certain assumptions and expectations of future events that are subject to risks and uncertainties. Actual results and trends may differ materially from historical results or those expressed or implied in any such forward-looking statements depending on a variety of factors. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in any forward-looking statement in this Corporate Profile, see the section titled "Risk Factors" in the Company's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission, as well as other reports that the Company files from time to time with the Securities and Exchange Commission. The Company undertakes no obligation to update publicly any forward-looking statement for any reason, except as required by law, even as new information becomes available or other events occur in the future. This material is intended for informational purposes only and is not intended to solicit the purchase or sale of the Company's securities.

CORPORATE DEVELOPMENTS

August 17, 2005 - ADVENTRX to Present at the 2005 San Diego Growth Conference on August 19

August 12, 2005 - ADVENTRX Expands Board Membership

August 12, 2005 - ADVENTRX Announces 2005 Second Quarter Financial Results

August 1, 2005 - ADVENTRX Completes \$20 Million Private Placement with Carl Icahn as Largest Investor

July 26, 2005 - ADVENTRX Presents Positive Thiovir™ Data at IAS 2005 Conference

July 22, 2005 - ADVENTRX raises \$20 Million in Common Stock Private Placement with Carl Icahn as Largest Investor

July 5, 2005 - ADVENTRX Joins The Russell Investment Group's New Russell Microcap™ Index

June 20, 2005 - ADVENTRX Presents Response Data For Total Enrollment In Cofactor Phase II Metastatic Colorectal Cancer Trial

May 31, 2005 - ADVENTRX Initiates Patient Treatment In international, CoFactor Phase IIb Metastatic Colorectal Clinical Trial

May 13, 2005 - ADVENTRX Reports Preliminary Phase II Trial Results with CoFactor in Metastatic Colorectal Cancer

RECENT FINANCIAL RESULTS

For the 6 months ended June 30, 2005, ADVENTRX reported a net loss of \$6.2 million, or \$0.11 per share, and had cash and cash equivalents of approximately \$8.1 million.

